26
total announcements
NEULANDLAB.BO · 15 min delayed
Key Stats · Yahoo Finance · as of 29 Oct 2026
Market Cap
₹25,680 Cr
P/E (TTM)
51.0
P/E (Forward)
41.2
EPS (TTM)
₹392.40
52W Low
₹11,500.00
52W High
₹24,235.05
Dividend Yield
0.18%
Beta
0.28
Price / Book
13.7
Debt / Equity
16.1
Revenue (TTM)
₹2,372 Cr
Gross Margin
55.17%
Operating Margin
30.60%
Neuland Laboratories Ltd
Neuland Laboratories Ltd has received an intimation from a shareholder regarding the loss of share certificate(s) and has requested for issuance of entitlement letter or direct credit of shares.
Neuland Laboratories Ltd
Neuland Laboratories Ltd has announced the schedule of its Q2 FY 2027 Earnings Call, which will be held on November 03, 2026 at 17:30 Hrs (IST).
Neuland Laboratories Ltd
Neuland Laboratories Ltd has announced the opening of a Special Window for transfer and dematerialization of physical shares, as per SEBI Circular No. HO/38/13/11(2)2026-MIRSD-PoD/I/3750/2026.
Neuland Laboratories Ltd
Neuland Laboratories Ltd has scheduled a Board Meeting on November 3, 2026, to consider and approve the unaudited Financial Results for the quarter and half year ended September 30, 2026.
Neuland Laboratories Ltd
Neuland Laboratories Ltd has received an Establishment Inspection Report (EIR) from the US FDA after an inspection at its Unit 3 manufacturing facility. The inspection, conducted from August 10, 2026 to August 14, 2026, has been concluded as 'closed'.
Neuland Laboratories Ltd
Neuland Laboratories Ltd has submitted a certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 2026, regarding dematerialization and rematerialization of securities.
Neuland Laboratories Ltd
Neuland Laboratories Ltd has announced the closure of its trading window from October 1, 2026, until 48 hours after the declaration of financial results for the quarter and half year ended September 30, 2026.
Neuland Laboratories Ltd
Neuland Laboratories Ltd has announced its participation in a group analyst/institutional investor meeting from September 23-25, 2026, in Singapore.
Neuland Laboratories Ltd
Neuland Laboratories Ltd has announced that Crisil Ratings has reaffirmed its credit rating as CRISIL A+/ Positive with a revised outlook to 'Positive' and CRISIL A1 for short-term rating.
Neuland Laboratories Ltd
Neuland Laboratories Ltd has published a newspaper advertisement regarding the opening of a Special Window for transfer and dematerialization of physical shares, as per SEBI Circular No. HO/38/13/11(2)2026-MIRSD-PoD/I/3750/2026, in the Financial Express and Nava Telangana on August 22, 2026.
Neuland Laboratories Ltd
Malabar India Fund Ltd has disclosed selling 2,72,634 equity shares of Neuland Laboratories Ltd in the secondary market, resulting in a 2.12% stake reduction.
Neuland Laboratories Ltd
Neuland Laboratories Ltd has informed that the US FDA has inspected its Unit 3 manufacturing facility and issued a Form 483 with one observation regarding procedural improvements in water and environmental monitoring.
Neuland Laboratories Ltd
Neuland Laboratories Ltd reported Q1FY27 earnings with a 16.3% revenue growth to INR650.1 crores, driven by commercial CMS projects. EBITDA margin improved to 35.5% and profit after tax stood at INR147.4 crores. Working capital efficiency improved with a reduction in working capital days from 137 to 84 days.
Neuland Laboratories Ltd
Neuland Laboratories Ltd has announced a schedule of analyst/institutional investor meetings on August 12, 2026, at Emkay Confluence 2026 in Mumbai.
Neuland Laboratories Ltd
Neuland Laboratories Ltd published copies of newspaper advertisement regarding financial results for the quarter ended June 30, 2026, as per Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015.
Neuland Laboratories Ltd
Neuland Laboratories Ltd has made available the audio recording of its earnings call for the quarter ended June 30, 2026, conducted on August 5, 2026.
Neuland Laboratories Ltd
Neuland Laboratories Ltd has announced the enhancement of its manufacturing capacity at Unit 1 located at Bonthapally Village, Gummadidala Mandal, Sangareddy District, Telangana. The company will add 18 KL of capacity, with an investment of Rs. 39.8 crores, to be completed within 6-7 months. The company has also executed a corporate guarantee of Rs. 40 crores in favour of Gland Pharma Limited for a loan licence agreement to establish dedicated manufacturing capacity and incur capital expenditure for certain products.
Neuland Laboratories Ltd
Neuland Laboratories Ltd has announced unaudited financial results for the quarter ended June 30, 2026, and has also approved the execution of a corporate guarantee of Rs. 40 crores in favour of Gland Pharma Limited, and enhancement of manufacturing capacity at Unit 1.
Neuland Laboratories Ltd
Neuland Laboratories Ltd has announced its Q1FY27 financial results, with total income at Rs. 650.1 crore, EBITDA at Rs. 231.1 crore, and PAT at Rs. 147.4 crore, showing significant year-over-year growth. The company's working capital days of sale decreased to 84 days in Q1FY27 from 137 days in Q4FY26, and capex outflow was Rs. 122 Cr in Q1FY27.
Neuland Laboratories Ltd
Neuland Laboratories Ltd announced its financial results for the quarter ended June 30, 2026, with total income at Rs.650.1 crore, EBITDA at Rs.231.1 crore, and EPS at Rs.114.9.